Jump to main content
Jump to site search

Issue 19, 2014
Previous Article Next Article

Water soluble multiarm-polyethylene glycol–betulinic acid prodrugs: design, synthesis, and in vivo effectiveness

Author affiliations

Abstract

Betulinic acid (BA) is a new type of cancer-fighting drug, but it is limited by its low water solubility and relatively short half-life in clinical applications. To overcome the shortcomings, BA prodrugs were prepared by using multiarm-polyethylene glycol linkers. The prodrugs exhibited high drug loading capacity (3.26–11.81 wt%), high water solubility (290–750 fold of free BA), and excellent in vitro anticancer activity. Subsequent tumor xenograft assays demonstrated the superior therapeutic effect of BA prodrugs on inhibition of tumor growth compared with free BA. Multiple intravenous injection of BA prodrugs equivalent to 10 mg of BA per kg resulted in the decrease of an established implanted murine Lewis lung carcinoma (percent tumor growth inhibition after treatment on day 20, 72.1–90.7%) in mice. These results strongly supported that the BA prodrugs are promising for cancer therapy.

Graphical abstract: Water soluble multiarm-polyethylene glycol–betulinic acid prodrugs: design, synthesis, and in vivo effectiveness

Back to tab navigation

Supplementary files

Publication details

The article was received on 09 May 2014, accepted on 12 Jun 2014 and first published on 13 Jun 2014


Article type: Paper
DOI: 10.1039/C4PY00648H
Author version available: Download Author version (PDF)
Citation: Polym. Chem., 2014,5, 5775-5783
  •   Request permissions

    Water soluble multiarm-polyethylene glycol–betulinic acid prodrugs: design, synthesis, and in vivo effectiveness

    L. Dai, D. Li, J. Cheng, J. Liu, L. Deng, L. Wang, J. Lei and J. He, Polym. Chem., 2014, 5, 5775
    DOI: 10.1039/C4PY00648H

Search articles by author

Spotlight

Advertisements